Champagne corks are flying for investors in emerging cancer therapy company Chimeric Therapeutics, which had a stellar start to listed life, thanks to its shares soaring more than 60 per cent in opening trade.
The business has just begun a phase-one clinical trial of its CAR-T therapy for recurrent glioblastoma (brain cancer) in the US, having successfully licensed the early-stage therapy from the Los Angeles-based City of Hope cancer treatment and research centre.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
